Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Pelton

Pediatric Infectious Diseases Boston, MA Medical Doctor

NPI 1891777223 CMS profile 222180

850 Harrison Ave, Yacc5, Boston, MA 02118

Open in the dashboard

General payments

$387,988

147 records reported · program years 2019–2025

Research payments

$72,219

Paid to them · 3 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,487,072 paid to institutions, not to them · program years 2020–2025

Through program year 2025, Stephen Pelton of Boston, MA is reported in the CMS Open Payments database as having received $387,988 across 147 general payments and $72,219 in research payments paid to them. Separately, studies naming them as principal investigator received $2,487,072 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatric Infectious Diseases profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $89,709 12
2025 Research $67,350 2
2024 General $20,547 5
2024 Research $4,869 1
2023 General $48,016 19
2022 General $48,544 28
2021 General $34,282 16
2020 General $82,629 24
2019 General $64,260 43

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Pelton
  • Pediatric Infectious Diseases median
  • Middle half of Pediatric Infectious Diseases
  • National median

In program year 2025, general payments to Stephen Pelton were reported at $89,709. Among 311 Pediatric Infectious Diseases profiles paid that year, the median was $126 and the middle half received between $41 and $2,094.

Show as a table
Year Stephen Pelton Pediatric Infectious Diseases median Middle half National median
2019 $64,260 $175 $34–$2,175 $163
2020 $82,629 $521 $34–$6,009 $114
2021 $34,282 $1,077 $39–$4,557 $132
2022 $48,544 $232 $53–$6,196 $149
2023 $48,016 $140 $52–$4,662 $160
2024 $20,547 $198 $52–$3,860 $164
2025 $89,709 $126 $41–$2,094 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $166,920 33 payments
  2. Merck Sharp & Dohme Corporation $64,466 57 payments
  3. Sanofi US Services Inc. $57,900 2 payments
  4. Seqirus USA Inc $46,184 17 payments
  5. Sanofi Pasteur Inc. $30,274 22 payments
  6. Pfizer International LLC $16,271 8 payments
  7. GlaxoSmithKline, LLC. $5,973 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $268,347 61 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $58,653 25 payments
  3. Honoraria $35,628 9 payments
  4. Travel and Lodging $24,299 28 payments
  5. Food and Beverage $1,061 24 payments
Products named General payments · program years 2019–2025
  1. PREVNAR 20 Vaccines $84,901 16 payments
  2. PREVNAR - 13 $36,878 11 payments
  3. PREVNAR 13 $29,063 6 payments
  4. MENACYW CONJUGATE VACCINE $8,697 3 payments
  5. PNEUMOVAX 23 $7,861 10 payments
  6. PREVNAR 20 Vaccines $7,600 3 payments
  7. FLUCELVAX QUADRIVALENT $6,039 3 payments
  8. V114 $1,275 2 payments
  9. NO PRODUCT DISCUSSED $880 8 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Sanofi Pasteur Inc. $67,350 2 payments
  2. Merck Sharp & Dohme Corporation $4,869 1 payment

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Infectious Diseases in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record